CWRU grants licensing agreement to Bioptigen for FDOCT technology

NewsGuard 100/100 Score

CWRU licenses OCT technology

Case Western Reserve University and University Hospitals Case Medical Center have granted to Bioptigen, of Research Triangle Park, N.C ., an exclusive intellectual property licensing agreement for Fourier domain optical coherence tomography (FDOCT), an imaging technology developed from research at the university's Department of Biomedical Engineering.

Advances in functional FDOCT are expected to enhance the early diagnosis and treatment of eye diseases, most notably diabetic retinopathy, which affects many of the 15 million Americans suffering from diabetes. These functional capabilities include Color Doppler FDOCT for visualizing and quantifying blood flow and Spectroscopic FDOCT for imaged tissues and fluids.

The licensed technology was created by Joseph Izatt, formerly on the biomedical engineering faculty at Case Western Reserve and now part of the biomedical engineering faculty at Duke University, and Andrew Rollins, Warren E. Rupp associate professor of biomedical engineering at Case Western Reserve.

Izatt, director, chairman and chief technology officer at Bioptigen, joined Duke in 2001 where he is professor of biomedical engineering and ophthalmology and program director for Biophotonics at the Fitzpatrick Center for Photonics.

"Observed changes in blood flow with functional FDOCT can help diagnose and mark progress of diseases and treatment for a number of eye diseases, especially in older patients," Rollins said.

The early validation of the technology is the result of a collaborative endeavor with University Hospitals Case Medical Center.

"We are pleased to play a key role in bringing this technology from the research lab to use in patients," said Phil Cola, vice president of research, University Hospitals Case Medical Center. "This technology promises to help patients struggling with eye disease."

In cooperation with Case Western Reserve and Duke, Bioptigen has commercialized ultra-high resolution FDOCT imaging systems providing researchers and clinicians with the tools to study, identify, track and treat eye disease, from the cornea to the retina and at the very earliest stages.

"Bioptigen is very pleased to extend its relationship with Case through this new technology agreement. The intellectual property licensed by Case is fundamental to our ability to provide the highest performance FDOCT imaging system today and to develop new clinical tools that will dramatically extend the clinical value of FDOCT into the future," said Eric Buckland, director, president and chief executive officer of Bioptigen.

"As part of the licensing agreement, Case will become an equity partner in Bioptigen, further strengthening our relationship," said Michael Haag, director of biomedical licensing at Case. Other terms of the agreement were not disclosed.

"We look forward to working with Bioptigen to incorporate the Case technology and expand their product portfolio to address medical disciplines beyond ocular imaging," Haag said.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
New machine learning model achieves breakthrough in heart disease prediction with over 95% accuracy